רדאר קליני AI | ||
|---|---|---|
הניסוי הקליני NCT06960720 עבור סרטן השד, עייפות הוא מגייס. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן. | ||
ניסוי אחד תואם לקריטריוני המסנן
תצוגת כרטיסים
חזרה לחיפוש
אוניברסיטת וירג'יניה המערביתLifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
פרטי הניסויים הקליניים זמינים בעיקר באנגלית. רדאר קליני AI יכול לעזור! לחץ על 'קבל הסבר' כדי לצפות ולשוחח על מידע מהניסוי בשפה המועדפת עליך.
הניסוי הקליני NCT06960720 הוא מחקר מסוג מתערב עבור סרטן השד, עייפות, שנמצא כעת במצב מגייס. המחקר התחיל ב-13 באוקטובר 2025 ומתוכנן לכלול 60 משתתפים. המחקר מנוהל על ידי אוניברסיטת וירג'יניה המערבית וצפוי להסתיים ב-1 באוגוסט 2027. מידע זה עודכן לאחרונה באתר ClinicalTrials.gov ב-31 באוקטובר 2025.
סיכום קצר
The long-term goal of this project is to improve the implementation of tailored resistance exercise interventions for Appalachian breast cancer survivors. To achieve this goal, the primary objective is to enhance the understanding of how biological, psychological, and social factors interact to influence readiness for behavior change around resistance exercise in this unique population. The primary aim is to evaluate the feasibility of delivering the Strength After Breast Cancer (SABC) program, focusing on how socioeconomic status (SES) and allostatic load (AL) scores influence adherence and dropout rates. The Investigators will also further examine how self-efficacy, outcome expectations, and social support influence behavior change related to resistance exercise participation. The central hypothesis is that participants with lower SES will report geographic or financial constraints, receive reduced support from family or peers, have low confidence in their ability to exercise, and demonstrate lower adherence rates.
Participants will:
- Use a clear, step-by-step guide for safe, progressive strength training using a resistance exercise program tailored specifically for breast cancer survivors for a duration of 3 months
- Keep an exercise log and complete questionnaires
כותרת רשמית
Lifting More Than Weights: Feasibility of Implementing a Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
מצבים רפואיים
סרטן השדעייפותמזהי מחקר נוספים
- 2501103633
מספר NCT
תחילת המחקר (בפועל)
2025-10-13
עדכון אחרון שפורסם
2025-10-31
סיום המחקר (מוערך)
2027-08
השתתפות (מוערכת)
60
סוג המחקר
מתערב
שלב
לא זמין
סטטוס
מגייס
מילות מפתח
Strength After Breast Cancer
Allostatic load
Cancer Related Fatigue
Allostatic load
Cancer Related Fatigue
מטרה ראשית
טיפול תמיכה
הקצאת טיפול
ללא רנדומיזציה
דגם מתערב
שיוך מקבילי
עיוורון
אין (תווית פתוחה)
זרועות / התערבויות
| קבוצת משתתפים/זרוע | התערבות/טיפול |
|---|---|
משווה פעילStrength After Breast Cancer (SABC) Lower SES Strength after Breast Cancer (SABC) is an evidence-based exercise program that improves body composition, body image, strength, and upper body using initial supervised sessions followed by unsupervised sessions with follow-up as needed. | תרגילי התנגדות Twice-weekly resistance exercises completed in 45 minutes using resistance bands and a physical therapy workout plan. |
משווה פעילStrength After Breast Cancer (SABC) Higher SES Strength after Breast Cancer (SABC) is an evidence-based exercise program that improves body composition, body image, strength, and upper body using initial supervised sessions followed by unsupervised sessions with follow-up as needed. | תרגילי התנגדות Twice-weekly resistance exercises completed in 45 minutes using resistance bands and a physical therapy workout plan. |
תוצאה ראשית
תוצאה משנית
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Dropout Rate - Lower SES | Percentage of participants in the lower SES group who drop out of the program | 3 Months |
Dropout Rate - Higher SES | Percentage of participants in the higher SES group who drop out of the program | 3 Months |
Overall Dropout Rate | Percentage of participants who drop out of the program. | 3 Months |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Adherence Rate - Lower SES | Percentage of participants in the lower SES group completing ≥ 75% of intervention activities and all scheduled assessments. | 3 Months |
Adherence Rate - Higher SES | Percentage of participants in the higher SES group completing ≥ 75% of intervention activities and all scheduled assessments | 3 Months |
Overall Adherence Rate | Percentage of participants completing ≥ 75% of intervention activities and all scheduled assessments. | 3 Months |
קריטריוני זכאות
גילאים מוערכים למחקר
מבוגר, מבוגר יותר
גיל מינימלי למחקר
18 Years
מגדרים מוערכים למחקר
נקבה
- Subjects must have histologically or cytologically confirmed Breast Cancer; any tumor molecular subtype can be enrolled.
- Subjects must have been diagnosed with non-metastatic breast cancer, defined as stage 0, I, II, or III (according to the American Joint Committee on Cancer Tumor, Node, Metastasis staging system), and must be between one and three years post-diagnosis at the time of enrollment. With treatment being received from the West Virginia University (WVU) Cancer Institute.
- Any severity or report of fatigue. This can be done through a subjective report documented by any healthcare professional or through a screening tool like the enhanced distress thermometer.
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
- Subjects who are pregnant (first or second trimester) or breastfeeding must receive additional approval from their obstetrics and gynecology physician for participation. Only individuals with a singleton pregnancy (no multiple gestations) will be eligible for participation. Pregnant participants must be in their first or second trimester at the time of enrollment to ensure they can complete the full three-month program before childbirth. Multiple gestations are associated with higher risks of pregnancy complications, increased physical limitations, and a greater likelihood of preterm delivery, which may prevent completion of the program.
- Male biological gender. Males will be excluded from the study due to the rarity of male breast cancer and the variability gender creates on AL scores.
- Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, active alcoholism, or psychiatric illness/social situations that would limit compliance with study requirements.
- Subjects with pregnancy beyond the second trimester at the time of enrollment, as later stages of pregnancy may prevent completion of the full three-month program.
- Subjects who are pregnant with multiple gestations (e.g., twins, triplets, or higher-order pregnancies) due to the increased risk of pregnancy-related complications, physical limitations, and the likelihood of preterm delivery, which may interfere with program completion.
- Subjects whose self-reported household income is above or below the median household income in Appalachia ($61,688) and for whom the target enrollment of 30 participants in that respective SES group (higher or lower) has already been met at the time of screening, as representation of both SES groups is required for the study.
אוניברסיטת וירג'יניה המערבית54 ניסויים קליניים פעילים לחקורהמשתתף האחראי למחקר
Megan Clark, חוקר ראשי, Associate Professor, West Virginia University
איש קשר מרכזי למחקר
צור קשר: Megan Clark, MD, 304-974-3912, [email protected]
צור קשר: McKinzey K Dierkes, DPT, [email protected]
1 מיקומי המחקר ב-1 מדינות
West Virginia
West Virginia University, Morgantown, West Virginia, 26506, United States
Tara Riddle, צור קשר, 3049065228, [email protected]
Megan Clark, MD, חוקר ראשי
מגייס